Literature DB >> 6330195

Inotropic drugs and their mechanisms of action.

H Scholz.   

Abstract

This report describes various old and new positive inotropic drugs with respect to their mechanisms of action. Drugs with established cardiotonic effects include cardiac glycosides, beta 1-adrenergic agents, glucagon, histamine and the methylxanthines. New agents discussed are prenalterol, beta 2- and alpha-adrenergic drugs, amrinone and sulmazole. Prenalterol is a beta 1-adrenergic agent. Beta 2-adrenergic drugs, amrinone and sulmazole, combine a positive inotropic and a vasodilator effect. The latter resemble theophylline and other methylxanthines in that they appear to act mainly as phosphodiesterase inhibitors with a subsequent increase in cyclic adenosine monophosphate (cAMP). The mechanism of the positive inotropic effect of alpha-adrenergic stimulating agents (for example, phenylephrine) is unknown. It is independent of the cAMP system and is not accompanied by changes in frequency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330195     DOI: 10.1016/s0735-1097(84)80231-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

1.  Ionic currents contributing to the action potential in single ventricular myocytes of the guinea pig studied with action potential clamp.

Authors:  T Doerr; R Denger; A Doerr; W Trautwein
Journal:  Pflugers Arch       Date:  1990-05       Impact factor: 3.657

2.  Relationship of plasma renin activity with caffeine intake and physical training in mild hypertensive men. HARVEST Study Group.

Authors:  P Palatini; C Canali; G R Graniero; G Rossi; R de Toni; M Santonastaso; M dal Follo; G Zanata; E Ferrarese; P Mormino; A C Pessina
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

3.  Electrophysiological effects mediated by the stimulation of cardiac beta 2-adrenoceptors with tulobuterol.

Authors:  A Mugelli; S Amerini; P De Bonfioli Cavalcabo; E Cerbai; S Visentin
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

4.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

Review 5.  Selective updates on mechanisms of action of positive inotropic agents.

Authors:  G Grupp
Journal:  Mol Cell Biochem       Date:  1987-08       Impact factor: 3.396

Review 6.  The effectiveness of inotropic agents in isolated cardiac preparations from the human heart.

Authors:  E Erdmann
Journal:  Klin Wochenschr       Date:  1988-01-04

Review 7.  New mechanisms for positive inotropic agents: focus on the discovery and development of imazodan.

Authors:  R E Weishaar; D Kobylarz-Singer; B A Klinkefus
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

8.  Successful Identification of Cardiac Troponin Calcium Sensitizers Using a Combination of Virtual Screening and ROC Analysis of Known Troponin C Binders.

Authors:  Melanie L Aprahamian; Svetlana B Tikunova; Morgan V Price; Andres F Cuesta; Jonathan P Davis; Steffen Lindert
Journal:  J Chem Inf Model       Date:  2017-11-16       Impact factor: 4.956

9.  Coffee consumption and risk of heart failure in men: an analysis from the Cohort of Swedish Men.

Authors:  Hanna N Ahmed; Emily B Levitan; Alicja Wolk; Murray A Mittleman
Journal:  Am Heart J       Date:  2009-08-22       Impact factor: 4.749

Review 10.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.